Open AccessIntravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta
Author(s) -
Pukhraj Rishi,
Ekta Rishi,
A. Venkatraman
Publication year - 2012
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.95882
Subject(s) - medicine , osteogenesis imperfecta , choroidal neovascularization , fundus (uterus) , bevacizumab , ophthalmology , complication , choroid , surgery , visual acuity , retina , chemotherapy , pathology , physics , optics
A 12-year-old girl, diagnosed of osteogenesis imperfecta, presented with sudden visual loss in the left eye. Investigations revealed an active choroidal neovascular membrane. She underwent treatment with intravitreal Bevacizumab (1.25 mg/0.05 ml). Follow-up at 1 month revealed the development of lacquer crack running through the macula, underlying the fovea. The patient received two re-treatments at 1-month intervals, following which the choroidal neovascularization (CNV) regressed completely. However, further progression of lacquer cracks was noted. At the last follow-up, 6 months following the last injection, the fundus remained stable and vision was maintained at 20/200. Considering the natural history of the disease and the increased risk of rupture of the Bruch's membrane in such eyes, the possible complication of a lacquer crack developing must be borne in mind, before initiating treatment.